Anika to Showcase HYALOFAST at the International Cartilage Regeneration & Joint Preservation Society (ICRS) Focus Meeting in ...
December 12 2018 - 8:00AM
Business Wire
Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated
orthopedic and regenerative medicines company specializing in
therapeutics based on its proprietary hyaluronic acid ("HA")
technology, today announced plans to showcase its entire
Orthobiologics franchise, including HYALOFAST, at the upcoming ICRS
Focus Meeting in Milan, Italy at the Humanitas Research University.
The ICRS is the main forum for international collaboration in
cartilaginous tissue research and joint preservation, with 1300
active members from 65 countries.
HYALOFAST is a non-woven, single-step, off-the-shelf,
biodegradable HA-based scaffold for hyaline-like cartilage
regeneration to treat cartilage injuries and defects. HYALOFAST is
commercially available in approximately 15 countries and has been
used to successfully treat more than 15,000 patients
internationally, and with strong eight-year patient follow-up data.
HYALOFAST is pending regulatory submission in the United States and
its FastTRACK Phase III trial is currently enrolling patients
across the U.S. and Europe.
“The ICRS Focus Meting in Milan is an excellent venue to further
showcase the significant advantages of our entire Orthobiologics
franchise before a collection of world-renowned experts in the
field of cartilage repair and regeneration,” said Joseph Darling,
President and CEO, Anika Therapeutics. “We believe that continuing
this peer-to-peer dialogue and technical training is central to
further advancing the HYALOFAST Phase III clinical trial, as well
as increasing commercial adoption. HYALOFAST is a truly remarkable
advancement in the treatment of cartilage injuries and defects due
to its flexible minimally-invasive means of application and
adaptive fit to individual patient needs.”
HYALOFAST will be featured at the International Cartilage
Regeneration and Joint Preservation Society (ICRS) Focus Meeting in
Milan, Italy during a technical session. The meeting, which will be
attended by many of the world’s leading cartilage specialists, will
showcase HYALOFAST as part of its “RE-LIVE SURGERY SESSIONS” and
its clinical data program.
HYALOFAST Technical SessionTitle: “Scaffolds: How to do
It. Re-live Surgery and Relevant Results”Presenter: Dr. Alberto
Gobbi, OASI Bioresearch Foundation, Milano – ItalyDate/Time:
December 14, 2018 at 9:30 – 10:15am
Company-Sponsored BoothAnika will be a Gold Sponsor and
will host a booth (#12) featuring guest physicians leading guided,
hands-on demonstrations of HYALOFAST procedures using the HYALOFAST
Arthroscopic Virtual Surgery Simulator. The company will also host
“watch & try” sessions at the Anika booth.
About ICRSThe ICRS (International Cartilage Regeneration
and Preservation Society) is the main forum for international
collaboration in cartilaginous tissue research that brings together
basic scientists, clinical researchers, physicians and members of
industry, engaged or interested in the field of articular biology,
its genetic basis and regenerative medicine. It provides continuing
education and training to physicians and scientists with an active
interest in the prevention and treatment of joint disease to
improve patient care through regenerative medicine approaches.
2018 HYALOFAST Publications
1.
Gobbi A., et al. Use of bone marrow
aspirate concentrate combined with hyaluronan-based scaffold for
early osteoarthritis in athletes. Football Medicine Outcomes
Abstract book XXVII Isokinetic Medical Group International
Conference – Camp Nou, Barcelona 2-4 June 2018. Ed Calzetti &
Mariucci. Page 442.
2.
Sofu H. et al. Clinical and radiographic
outcomes of chitosan-glycerol phosphate/blood implant are similar
with hyaluronic acid-based cell-free scaffold in the treatment of
focal osteochondral lesions of the knee joint. Knee Surg Sports
Traumatol Arthrosc. 2018 Aug 1. (Epub ahead of print).
3.
Gollwitzer H. Operative Therapie -
Knorpelschäden der Hϋfte Einzeitiges arthroskopisches Verfahren zur
Regeneration. Sportärztezeitung 03/2018 (Cartilage Damage to the
Hip. One-Stage Arthroscopic Method of Regeneration).
About Anika Therapeutics, Inc.Anika Therapeutics,
Inc. (NASDAQ: ANIK) is a global, integrated orthopedic
medicines company based in Bedford, Massachusetts. Anika is
committed to improving the lives of patients with degenerative
orthopedic diseases and traumatic conditions with clinically
meaningful therapies along the continuum of care, from palliative
pain management to regenerative tissue repair. The Company has over
two decades of global expertise developing, manufacturing, and
commercializing more than 20 products based on its
proprietary hyaluronic acid (HA) technology. Anika's
orthopedic medicine portfolio
includes ORTHOVISC®, MONOVISC®,
and CINGAL®, which alleviate pain and restore
joint function by replenishing depleted HA,
and HYALOFAST, a solid HA-based scaffold to aid
cartilage repair and regeneration. For more information about
Anika, please visit www.anikatherapeutics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181212005069/en/
For Investor Inquiries:Anika Therapeutics, Inc.Sylvia Cheung,
781-457-9000Chief Financial Officer
For Media Inquiries:W2O GroupSonal Vasudev, 917-523-1418
sonal@w2ogroup.com
Anika Therapeutics (NASDAQ:ANIK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Anika Therapeutics (NASDAQ:ANIK)
Historical Stock Chart
From Apr 2023 to Apr 2024